NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3 Meeting Abstract
| Authors: | Hussein, M. A.; Khan, G.; Chandana, S. R.; Cid, R. A. P.; Kiss, I.; Gallego, J.; Macarulla, T.; De la Fouchardiere, C.; Goetze, T.; Dean, A. P.; O'Reilly, E. M.; Wainberg, Z. A.; Lee, W. J.; Van Cutsem, E.; Hubner, R.; Paulson, A. S.; Bekaii-Saab, T. S.; Pant, S.; Maxwell, F.; Melisi, D. |
| Abstract Title: | NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3 |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401106 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.4136 |
| Notes: | Meeting Abstract: 4136 -- Source: Wos |
